Update: Poised for a pivotal year
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is the primary valuation driver, and Phase II data in H215 for stroke disability are the key event. Positive outcomes would signal a prospective breakthrough therapy for these patients and likely spark fresh investor/partnering interest. And with new legislation in Japan to accelerate the approval of stem cell products, there is potential to bring CTX to market earlier than currently expected in 2019.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.